CareDx, Inc Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023
November 08, 2023 at 04:17 pm EST
Share
CareDx, Inc reported earnings results for the third quarter and nine months ended September 30, 2023. For the third quarter, the company reported revenue was USD 67.19 million compared to USD 79.36 million a year ago. Net loss was USD 23.49 million compared to USD 16.94 million a year ago. Basic loss per share from continuing operations was USD 0.43 compared to USD 0.32 a year ago. Diluted loss per share from continuing operations was USD 0.43 compared to USD 0.32 a year ago.
For the nine months, revenue was USD 214.76 million compared to USD 239.41 million a year ago. Net loss was USD 72.19 million compared to USD 58.28 million a year ago. Basic loss per share from continuing operations was USD 1.34 compared to USD 1.09 a year ago. Diluted loss per share from continuing operations was USD 1.34 compared to USD 1.09 a year ago.
CareDx, Inc. is a precision medicine solutions company. The Company is focused on the discovery, development, and commercialization of clinically differentiated, diagnostic solutions for transplant patients and caregivers. The Company offers testing services, products, and patient and digital solutions along the pre- and post-transplant patient journey and is a provider of genomics-based information for transplant patients. Its commercially available testing services consist of AlloSure Kidney, a donor-derived cell-free DNA (dd-cfDNA) solution for kidney transplant patients; AlloMap Heart, a gene expression solution for heart transplant patients; AlloSure Heart, a dd-cfDNA solution for heart transplant patients, and AlloSure Lung, a dd-cfDNA solution for lung transplant patients. The Companyâs product portfolio includes AlloSeq Tx, QTYPE, Olerup SSP, AlloSeq HCT and AlloSeq cfDNA. It develops and provides diagnostic surveillance testing services for various transplant recipients.
CAREDX, INC 
